Neurology

Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer’s Disease

SinaptiStim™ – AD System provides personalized and precision-delivered electromagnetic therapeutic approach to treating cognitive and functional decline in Alzheimer’s disease...

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samplesIncrease...

BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society

- Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic data from...

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis

IBA expands its activities in Sub-Saharan Africa and signs contract with Sweden Ghana Medical Centre for an IntegraLab® PLUS in Accra, Ghana

New contract to provide broader access to diagnostics in emerging markets Louvain-La-Neuve, Belgium, October 13, 2022 – IBA (Ion Beam Applications S.A.,...

Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets

WARREN, N.J., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”), a pharmaceutical company advancing medicines to...

Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease

SAN DIEGO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic...

Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial

STS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to dateOver 8,000 migraine attacks treated with more...

error: Content is protected !!